EFFETTI DELL'UBIDECARENONE NEL TRATTAMENTO DELLO SCOMPENSO CARDIACO NEGLI ANZIANI

Translated title of the contribution: Effects of ubidecarenone in the treatment of heart failure in the elderly

P. Simonelli, A. M. Cicatiello, G. Simonelli, A. Cioppa, P. Ferrara, A. Ceriello, R. Abate, L. Del Mastro

Research output: Contribution to journalArticle

Abstract

The authors, after defining the epidemiological field of cardiac decompensation, analyse the physiopathologic grounds which are at the basis of the use of metabolic drugs. In particular they show the bioenergetic processes linked to the bioavailability of ATP have a key role in assuring cardiac contractility both at rest and under effort, and how a significant correlation has been shown between the indexes of the systolic and diastolic function, valued with scintigraphic, echocardiographic and invasive methods, and the contents of ATP, surveyed through endomyocardic biopsies, in decompensated human hearts. A review of the main international studies underlines the favourable effects of the use of the ubidecarenone (CoQ10) in cardiac decompensation therapy. In the end the authors show the data of their own experience of the use of CoQ10 in the treatment of the cardiac decompensation. After giving 100 mg/die of CoQ10 for seven months, there was observed a significant improvement of the echocardiographic indexes of the systolic function, of the cardiothoracic relation, of the subjective symptomatology and the objective reports. Authors conclude by asserting that there exists a rationality for the therapeutic treatment of cardiac decompensation offering new horizons in a pathology whose human and social costs will be more and more important in the future.

Original languageItalian
Pages (from-to)25-31
Number of pages7
JournalGazzetta Medica Italiana Archivio per le Scienze Mediche
Volume153
Issue number1
Publication statusPublished - 1994

Fingerprint

coenzyme Q10
Treatment Failure
Heart Failure
Adenosine Triphosphate
Therapeutics
Energy Metabolism
Biological Availability
Pathology
Biopsy
Costs and Cost Analysis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Simonelli, P., Cicatiello, A. M., Simonelli, G., Cioppa, A., Ferrara, P., Ceriello, A., ... Del Mastro, L. (1994). EFFETTI DELL'UBIDECARENONE NEL TRATTAMENTO DELLO SCOMPENSO CARDIACO NEGLI ANZIANI. Gazzetta Medica Italiana Archivio per le Scienze Mediche, 153(1), 25-31.

EFFETTI DELL'UBIDECARENONE NEL TRATTAMENTO DELLO SCOMPENSO CARDIACO NEGLI ANZIANI. / Simonelli, P.; Cicatiello, A. M.; Simonelli, G.; Cioppa, A.; Ferrara, P.; Ceriello, A.; Abate, R.; Del Mastro, L.

In: Gazzetta Medica Italiana Archivio per le Scienze Mediche, Vol. 153, No. 1, 1994, p. 25-31.

Research output: Contribution to journalArticle

Simonelli, P, Cicatiello, AM, Simonelli, G, Cioppa, A, Ferrara, P, Ceriello, A, Abate, R & Del Mastro, L 1994, 'EFFETTI DELL'UBIDECARENONE NEL TRATTAMENTO DELLO SCOMPENSO CARDIACO NEGLI ANZIANI', Gazzetta Medica Italiana Archivio per le Scienze Mediche, vol. 153, no. 1, pp. 25-31.
Simonelli, P. ; Cicatiello, A. M. ; Simonelli, G. ; Cioppa, A. ; Ferrara, P. ; Ceriello, A. ; Abate, R. ; Del Mastro, L. / EFFETTI DELL'UBIDECARENONE NEL TRATTAMENTO DELLO SCOMPENSO CARDIACO NEGLI ANZIANI. In: Gazzetta Medica Italiana Archivio per le Scienze Mediche. 1994 ; Vol. 153, No. 1. pp. 25-31.
@article{aeed9e45e465462096b26182c155dd65,
title = "EFFETTI DELL'UBIDECARENONE NEL TRATTAMENTO DELLO SCOMPENSO CARDIACO NEGLI ANZIANI",
abstract = "The authors, after defining the epidemiological field of cardiac decompensation, analyse the physiopathologic grounds which are at the basis of the use of metabolic drugs. In particular they show the bioenergetic processes linked to the bioavailability of ATP have a key role in assuring cardiac contractility both at rest and under effort, and how a significant correlation has been shown between the indexes of the systolic and diastolic function, valued with scintigraphic, echocardiographic and invasive methods, and the contents of ATP, surveyed through endomyocardic biopsies, in decompensated human hearts. A review of the main international studies underlines the favourable effects of the use of the ubidecarenone (CoQ10) in cardiac decompensation therapy. In the end the authors show the data of their own experience of the use of CoQ10 in the treatment of the cardiac decompensation. After giving 100 mg/die of CoQ10 for seven months, there was observed a significant improvement of the echocardiographic indexes of the systolic function, of the cardiothoracic relation, of the subjective symptomatology and the objective reports. Authors conclude by asserting that there exists a rationality for the therapeutic treatment of cardiac decompensation offering new horizons in a pathology whose human and social costs will be more and more important in the future.",
keywords = "ATP, heart failure, ubidecarenone",
author = "P. Simonelli and Cicatiello, {A. M.} and G. Simonelli and A. Cioppa and P. Ferrara and A. Ceriello and R. Abate and {Del Mastro}, L.",
year = "1994",
language = "Italian",
volume = "153",
pages = "25--31",
journal = "Gazzetta Medica Italiana Archivio per le Scienze Mediche",
issn = "0393-3660",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "1",

}

TY - JOUR

T1 - EFFETTI DELL'UBIDECARENONE NEL TRATTAMENTO DELLO SCOMPENSO CARDIACO NEGLI ANZIANI

AU - Simonelli, P.

AU - Cicatiello, A. M.

AU - Simonelli, G.

AU - Cioppa, A.

AU - Ferrara, P.

AU - Ceriello, A.

AU - Abate, R.

AU - Del Mastro, L.

PY - 1994

Y1 - 1994

N2 - The authors, after defining the epidemiological field of cardiac decompensation, analyse the physiopathologic grounds which are at the basis of the use of metabolic drugs. In particular they show the bioenergetic processes linked to the bioavailability of ATP have a key role in assuring cardiac contractility both at rest and under effort, and how a significant correlation has been shown between the indexes of the systolic and diastolic function, valued with scintigraphic, echocardiographic and invasive methods, and the contents of ATP, surveyed through endomyocardic biopsies, in decompensated human hearts. A review of the main international studies underlines the favourable effects of the use of the ubidecarenone (CoQ10) in cardiac decompensation therapy. In the end the authors show the data of their own experience of the use of CoQ10 in the treatment of the cardiac decompensation. After giving 100 mg/die of CoQ10 for seven months, there was observed a significant improvement of the echocardiographic indexes of the systolic function, of the cardiothoracic relation, of the subjective symptomatology and the objective reports. Authors conclude by asserting that there exists a rationality for the therapeutic treatment of cardiac decompensation offering new horizons in a pathology whose human and social costs will be more and more important in the future.

AB - The authors, after defining the epidemiological field of cardiac decompensation, analyse the physiopathologic grounds which are at the basis of the use of metabolic drugs. In particular they show the bioenergetic processes linked to the bioavailability of ATP have a key role in assuring cardiac contractility both at rest and under effort, and how a significant correlation has been shown between the indexes of the systolic and diastolic function, valued with scintigraphic, echocardiographic and invasive methods, and the contents of ATP, surveyed through endomyocardic biopsies, in decompensated human hearts. A review of the main international studies underlines the favourable effects of the use of the ubidecarenone (CoQ10) in cardiac decompensation therapy. In the end the authors show the data of their own experience of the use of CoQ10 in the treatment of the cardiac decompensation. After giving 100 mg/die of CoQ10 for seven months, there was observed a significant improvement of the echocardiographic indexes of the systolic function, of the cardiothoracic relation, of the subjective symptomatology and the objective reports. Authors conclude by asserting that there exists a rationality for the therapeutic treatment of cardiac decompensation offering new horizons in a pathology whose human and social costs will be more and more important in the future.

KW - ATP

KW - heart failure

KW - ubidecarenone

UR - http://www.scopus.com/inward/record.url?scp=0028275474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028275474&partnerID=8YFLogxK

M3 - Articolo

VL - 153

SP - 25

EP - 31

JO - Gazzetta Medica Italiana Archivio per le Scienze Mediche

JF - Gazzetta Medica Italiana Archivio per le Scienze Mediche

SN - 0393-3660

IS - 1

ER -